Skip to content
Open access · US-GOV via ClinicalTrials.gov Clinical trial

Impact of Lp299v on Vascular Aging in Healthy Adults

Authors not listed

Medical College of Wisconsin · 2023

Abstract

Emerging data suggest the gut microbiota regulates multiple mechanisms related to vascular aging, but no intervention targeting the gut microbiota has been tested in older adults without cardiovascular risk factors or cardiovascular disease. Early human data suggest an increase in potentially pathological gut metabolites such as trimethylamine-N-oxide (TMAO) are associated with older age, increased vascular stiffness, increased oxidative stress, and reduced nitric oxide (NO) bioavailability as evidenced by impaired endothelium-dependent vasodilation. Based on this data, the investigators hypothesize that supplementation with Lp299v will reverse human vascular aging in healthy older adults free of known traditional cardiovascular risk factors.

◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:

Read at source →

Provenance

Source
ClinicalTrials.gov
Canonical
link ↗
Fetched
2026-05-31 MST

Cite this

APA
Anonymous. (2023). Impact of Lp299v on Vascular Aging in Healthy Adults. <em>Medical College of Wisconsin</em>. https://clinicaltrials.gov/study/NCT05296395
Vancouver
Anonymous. Impact of Lp299v on Vascular Aging in Healthy Adults. Medical College of Wisconsin. 2023.
BibTeX
@misc{anon2023Impact, title = {Impact of Lp299v on Vascular Aging in Healthy Adults}, author = {Anonymous}, journal = {Medical College of Wisconsin}, year = {2023}, }

Research neighborhood

References, citing works, and semantically nearest findings. Click a node to open it.

Related findings